The pace of domestically innovative drugs gaining market approval will continue to accelerate, unleashing greater new vitality.
According to the 2021 annual report released by the pharmaceutical company, segments such as vaccines, medical devices, and healthcare services delivered impressive performance, while the pace of innovative drug approvals continued to accelerate. Additionally, several innovative pharmaceutical companies previously operating at a loss have seen their losses narrow or even turn profitable, thanks to the launch of blockbuster products. For instance, Junshi Biosciences experienced significant growth in revenue, increasing by 152.36% year-on-year, primarily driven by substantial gains from technology licensing income, newly added royalty revenues, and sales proceeds generated from the commercialization of toripalimab injection in the domestic market. Financial data indicates that Junshi Biosciences achieved an operating revenue of 4.025 billion yuan in 2021.
